NCT00729846

Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)

Combination Bevacizumab and Verteporfin (Standard and Reduced Fluence)in the Treatment of Neovascular Age-Related Macular Degeneration

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: California Retina Consultants · Academic / Other
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

To evaluate safety, visual acuity outcomes, persistence of choroidal neovascular leakage, and the number of treatments of combination intravitreal bevacizumab and verteporfin photodynamic therapy at standard or reduced fluence level in patients with subfoveal CNV due to age-related macular degeneration.

Conditions

• Age Related Macular Degeneration
• Choroidal Neovascularization
• Macular Edema

Interventions

Type	Name	Description
DRUG	Bevacizumab	Patients will receive intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.
DEVICE	verteporfin photodynamic therapy reduced fluence	Patients will receive combination verteporfin photodynamic therapy with stand fluence \[600mW/cm2\].
DEVICE	verteporfin photodynamic therapy standardfluence	Patients will receive combination verteporfin with photodynamic therapy at standard fluence \[600mw/cm2\].

Timeline

• Start date: 2006-05-01
• Primary completion: 2008-08-01
• Completion: 2009-07-01
• First posted: 2008-08-08
• Last updated: 2016-04-20
• Results posted: 2016-04-20

Locations

2 sites across 1 country: United States